The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of Thrombolytics for the Treatment of Thromboembolic Disease During Pregnancy
Abstract
The incidence of thromboembolic disease is increased during pregnancy. Prevention and treatment of thromboembolic disease can have a significant impact on the morbidity and mortality of pregnant women. Anticoagulation with heparin is the treatment of choice; however, in some instances this is inadequate or contraindicated. In the nonpregnant patient, alternative therapies have included surgical intervention or fibrinolytic agents. Traditionally, thrombolytic therapy has been considered a relative contraindication during pregnancy due to the maternal and fetal risk of hemorrhagic complications. Hence, no controlled trials of agents such as streptokinase, urokinase, or tissue plasminogen activator for the treatment of thromboembolic events during pregnancy, have been performed, or are currently feasible. Since 1961, 36 reports have been published describing the use of thrombolytic agents during pregnancy. In a review of the world's literature, 172 pregnant women affected with thromboembolic conditions were treated with thrombolytic medications. A maternal mortality rate of 1.2 percent was observed. Approximately 10 pregnancy losses were noted (5.8 percent). Hemorrhagic complications were reported in 8.1 percent of patients. We summarize the published literature on the use of thrombolytic agents during pregnancy and discuss the treatment success and reported complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risks to the Fetus of Anticoagulant Therapy During Pregnancy
Ginsberg, J. S., Hirsh, J., Turner, D. C., Levine, M. N., & Burrows, R. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646558 · Cited by 218
Cited by
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy340 · Cited by 2,292
ESC Guidelines on the management of cardiovascular diseases during pregnancy
Endorsed by the European Society of Gynecology (ESG), T. A. F. E. P. C. (., Authors/Task Force Members, Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., Cifkova, R., Ferreira, R., Foidart, J.-M., Gibbs, J. S. R., Gohlke-Baerwolf, C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr218 · Cited by 1,924
European Resuscitation Council Guidelines for Resuscitation 2015
Perkins, G. D., Handley, A. J., Koster, R. W., Castrén, M., Smyth, M. A., Olasveengen, T., Monsieurs, K. G., Raffay, V., Gräsner, J.-T., Wenzel, V., et al. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.07.015 · Cited by 1,287
European Resuscitation Council Guidelines for Resuscitation 2005
Soar, J., Deakin, C. D., Nolan, J. P., Abbas, G., Alfonzo, A., Handley, A. J., Lockey, D., Perkins, G. D., & Thies, K. (2005) · Resuscitation · doi:10.1016/j.resuscitation.2005.10.004 · Cited by 832
Metadata
- Authors
- Turrentine, M. A., Braems, G., & Ramirez, M. M.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 1995-07
- Volume
- 50
- Issue
- 7
- Pages
- 534-541
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2002371746
- Cited by
- 237
- References
- 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Thrombolytics for the Treatment of Thromboembolic Disease During Pregnancy. https://app.cochat.ai/papers/10.1097/00006254-199507000-00020
- The paper
- Turrentine, M. A., Braems, G., & Ramirez, M. M. (1995). Use of Thrombolytics for the Treatment of Thromboembolic Disease During Pregnancy. Obstetrical & Gynecological Survey. https://doi.org/10.1097/00006254-199507000-00020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.